Denusomab vs alendronate

MRCP Part 1 Community

119 followers

Posted by Lal Pandey | 6 days ago (Edited)

6 days ago (Edited)

I think Denusomab increases risk of infection not alendronate

Denusomab is RANKL inhibitor and Osteoclast deactivator. Both Denusomab and alendronate cause osteoclastic deactivation. But only Denusomab cause increased risk of infection in the form of Cellulitis . Reason being RANKL Inhibition by Denusomab not only causes RANKL Inhibition of Osteoclast but it calso causes inhibition of RANKL on T cells and Dendritic cells of immune system ----- Decreased Immune system --- Increased Risk of Infection especially in CKD Elderly and DM Patients

Question:

A 65-year-old woman undergoes her annual physical exam. She has a history of osteoporosis, with several minor fractures in the past. She mentions to her doctor that she's been experiencing persistent pain and discomfort in her back. Her doctor attributes this to her osteoporosis and prescribes a medication for it. She comes back a few weeks later complaining of the same pain, but now she also has a fever and increased fatigue. Her lab results show elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Which of the following medications was most likely prescribed initially by her doctor?

Options:

A)Alendronate

B)Ibuprofen

C)Paracetamol

D)Betamethasone

E)Aspirin

→ View this question

Denusomab vs alendronate

I think Denusomab increases risk of infection not alendronate

Question:

Options:

A)Alendronate

B)Ibuprofen

C)Paracetamol

D)Betamethasone

E)Aspirin

→ View this question